The Center for Medicare and Medicaid Innovation may introduce a five-year pilot model to expand access to weight loss drugs, while the Trump administration appears to be backing away from a campaig | The Trump administration has not adamantly pursued policies in support of in vitro fertilization coverage,

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the weight loss drugs, according to a new report.

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.